Answers are grounded in this paper and cite their sources.
Renal cell carcinoma (RCC) is a chemo-resistant malignancy. For many years the only treatment for advanced disease was immunotherapy; the cytokines IFN-α and IL-2 were widely used but offered limited objective response rates of 10–20% and only modest survival benefits in the majority of cases. The last decade has witnessed a marked increase in the availability of novel targeted therapies demonstrating anti-tumor activity and, more importantly, providing a meaningful impact on overall survival. However, to date, immunotherapy, in the form of high-dose IL-2, remains the only treatment modality able to induce durable complete remissions and/or cure in metastatic RCC, albeit in a small minority of patients. A priority for immunotherapy research should be to investigate strategies that may augment the effectiveness of immunomodulation and enable a greater proportion of patients with advanced RCC to benefit from this treatment. A number of approaches are discussed; combinations with molecularly targeted agents ...
No takes yet. Share an insight, caveat, or question.
Léary et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: